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Lower Sodium Intake and Risk of Headaches:
Results From the Trial of Nonpharmacologic
Interventions in the Elderly
Liwei Chen, MD, PhD, Zhenzhen Zhang, PhD, Wen Chen, MD, Paul K. Whelton, MD, and Lawrence J. Appel, MD
Objectives. To determine the effect of sodium (Na) reduction on occurrence of
headaches.
Methods. In the Trial of Nonpharmacologic Interventions in the Elderly, 975 men and
woman (aged 60–80 years) with hypertension were randomized to a Na-reduction in-
tervention or control group and were followed for up to 36 months. The study was
conducted between 1992 and 1995 at 4 clinical centers (Johns Hopkins University, Wake
Forest University School of Medicine, Robert Wood Johnson Medical School, and the
University of Tennessee).
Results.Mean difference in Na excretion between the Na-reduction intervention and
control groupwas signiﬁcant at each follow-up visit (P < .001) with an average difference
of 38.8 millimoles per 24 hours. The occurrence of headaches was signiﬁcantly lower
in the Na-reduction intervention group (10.5%) compared with control (14.3%) with
a hazard ratio of 0.59 (95% conﬁdence interval = 0.40, 0.88; P= .009). The risk of head-
aches was signiﬁcantly associated with average level of Na excretion during follow-up,
independent of most recent blood pressure. The relationship appeared to be nonlinear
with a spline relationship and a knot at 150 millimoles per 24 hours.
Conclusions. Reduced sodium intake, currently recommended for blood pressure
control, may also reduce the occurrence of headaches in older persons with hypertension.
(Am J Public Health. 2016;106:1270–1275. doi:10.2105/AJPH.2016.303143)
Headache is a common health problemin adults, resulting in approximately
18million physician visits in theUnited States
each year.1 Globally, the estimated lifetime
prevalence of headaches in adults is 66%.2
The most common types of headaches are
nonvascular and are commonly termed
“tension headaches.”1 Tension headaches
have been attributed to muscle spasm in
the head, neck, and shoulders in response to
stress, fatigue or environmental factors like
noise or bright lights.3 However, the path-
ophysiology of tension headaches is
uncertain.
Headaches have been associated with
elevated blood pressure (BP), including
sustained severe hypertension, malignant
hypertension, and paroxysmal hyperten-
sion.4 In the Hypertension Optimal
Treatment trial, in which participants were
randomized to 1 of 3 diastolic BP goals,
headaches were reduced in all treatment
groups, independent of BP goal and type
of antihypertensive drug.5
High sodium intake is associated with
elevated BP, and clinical trials have dem-
onstrated that sodium-reduction (NaD)
lowers BP in individuals with or without
hypertension.6–13 A high intake of sodium
potentially leads to headaches through
a direct effect on BP or indirectly through
a BP-independent mechanism. However,
few studies have investigated the
relationship of sodium intake to the oc-
currence of headaches. In preliminary
observations from the Trial of Non-
pharmacologic Interventions in the Elderly
(TONE), we reported that individuals who
were assigned to the NaD intervention
had a lower incidence of headaches.13 A
more recent analysis using data collected
from the Dietary Approaches to Stop
Hypertension (DASH)-sodium trial re-
ported that NaD was associated with
a lower risk of headaches,14 replicating
the earlier observation from the TONE
study. We aimed to expand on the
original observation from TONE by ex-
amining the relationship between sodium
intake and headaches, with a particular
focus on assessing dose–response
relationship.
METHODS
TONE was a multicenter, randomized
controlled trial designed to test the efﬁcacy of
nonpharmacologic interventions as a means
to control hypertension in the elderly.
A detailed description of the design and
methods of this trial has been published
elsewhere.15 Eligible individuals were aged
60 to 80 years, were community dwelling,
and had hypertension controlled on single
antihypertensive medication. Major exclu-
sion criteria included history of a heart attack
or stroke within the preceding 6 months,
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current angina pectoris, congestive heart
failure, insulin-dependent diabetes mellitus,
serious mental or physical illness, unexplained
or involuntary weight loss of 4.5 kilograms
or greater during the previous year, hyper-
creatinemia (> 2.0 mg/dL), hyperkalemia
(> 5.5 mmol/L), and anemia (hemoglobin
level < 11 g/dL).
We randomly assigned overweight
persons (body mass index [BMI; deﬁned as
weight in kilograms divided by the square
of height in meters] > 27.3 kg/m2 in men,
> 27.8 kg/m2 in women) to 1 of 4 groups
in a 2 · 2 factorial design (usual care, weight
loss alone, reduced sodium alone, or
combined weight loss and reduced
sodium). We assigned nonoverweight
persons to usual care or reduced sodium
intake. The NaD goal for the reduced
sodium groups, both NaD alone and NaD
combined with weight loss, was to achieve
and maintain a 24-hour dietary sodium
intake of 80 millimoles (1800 mg)
or less. Three months after the start of
intervention, we employed a standardized
protocol to gradually taper and withdraw
antihypertensive medication in participants
whose BP remained less than 150/90
millimeters of mercury.
The primary trial outcome was a com-
posite endpoint that included recurrence of
high BP, resumption of antihypertensive
medication, or a clinical cardiovascular
event. During follow-up, we restarted
antihypertensive medication if (1) systolic
BP was 190 millimeter of mercury or more
or diastolic BP was 110 millimeters of
mercury or more at a single visit (average of
3 BP measurements), (2) mean systolic BP
was 170 millimeters of mercury or more or
diastolic BP was 100 millimeters of mer-
cury or more over 2 consecutive visits
(average of 6 BP measurements), or (3)
mean systolic BP was 150 millimeters of
mercury or more or diastolic BP rose to
90 millimeters of mercury or more at 3
consecutive visits (average of 9 BP
measurements).
We enrolled participants between
August 30, 1992, and June 27, 1994. We
collected TONE data at 2 screening visits to
establish study eligibility, a randomization
visit, drug withdrawal visits (90 days after
the start of intervention), and 11 subsequent
quarterly follow-up visits (beginning
6 months after randomization). Closeout
visits occurred between July and December
1995. The median follow-up in TONE
was 29 months (range = 1–36 months).
We conducted the study at 4 clinical centers
(Johns Hopkins University, Wake Forest
University School of Medicine, Robert
Wood Johnson Medical School, and the
University of Tennessee).13 Staff members,
who were blinded to the participant’s
randomized treatment assignment, ob-
tained outcome information.
Variables
We estimated dietary sodium intake by
measurement of carefully collected 24-hour
urinary sodium excretion. We analyzed
urinary sodium levels by ﬂame photometry.13
In TONE we ascertained headaches by
participant self-report of an adverse event
at any follow-up visit. At each follow-up visit,
participants completed a brief self-reported
medical history and adverse events ques-
tionnaire. A study nurse evaluated any par-
ticipant who reported an intercurrent
health-related concern. If a participant re-
ported a medical problem that was poten-
tially serious (e.g., angina) or a symptom
that was severe (e.g., headache or chest pain)
the nurse completed an adverse event form.
A physician then reviewed and coded
the adverse event by type (e.g., stroke,
myocardial infarction, headache). We also
collected and coded the date of the event.
Both the nurse and physician were
unaware on the participant’s treatment
assignment.
Trained observers who were masked to
intervention assignment measured BP. At
each visit, we obtained 3 BP measurements
while participants rested in the seated posi-
tion. We collected detailed demographic and
socioeconomic information including age,
gender, race, physical activity, smoking
habits, and alcohol intake at baseline.15 We
also collected interval medical information,
medication use, and body weight measure-
ment at each visit.
Statistical Analyses
We expressed descriptive data for iden-
tiﬁcation of baseline characteristics as well
as urinary sodium excretion at each visit
as means (SD) for continuous variables
and counts (%) for categorical variables.
We used the Student t test and c2 test to
compare continuous variables and discrete
variables, respectively. For all the analyses,
the primary outcome was headache, which
we identiﬁed by means of adverse event
reports.
First, we compared incidence of headaches
between those in theNaD intervention group
(i.e., the NaD alone plus combined weight
loss and NaD interventions) and their
counterparts in the control group (i.e., usual
care plus weight loss alone interventions).We
used Kaplan-Meier plots to explore temporal
patterns for cumulative incidence
of headaches and Cox proportional
hazard regressions to estimate the hazard ratio
(HR) and 95% conﬁdence interval (CI) for
comparison of ﬁrst occurrence of a headache
between the 2 groups. Because this com-
parison was on the basis of randomized as-
signments, we only adjusted for variables that
were signiﬁcantly different between the NaD
intervention and control groups (i.e., time-
varying drug withdraw status and BPs).
Although we conducted the main analyses
between theNaD and control groups, we also
performed a sensitivity analysis to compare
headaches among the 4 original group as-
signments of the factorial design (i.e., usual
care, weight loss alone, NaD alone, and
combined weight loss and
NaD interventions).
Second, we examined whether there
were a dose–response relationship and
threshold effect between sodium intake and
the occurrence of headaches. The exposure
was 24-hour urinary sodium excretion,
measured as the average level during follow-
up. We used Cox proportional hazard re-
gressions to investigate the frequency of new
onset headaches, assessed as an adverse event
(incident headaches postrandomization). In
these models, we combined participants
from all intervention groups and we in-
cluded potential confounders such as age,
gender, race, physical activity, smoking, al-
cohol intake, headaches at baseline, average
weight loss during follow-up, and drug
withdraw status (time-varying variable) in
the adjusted analyses. To explore whether
the relationship of headaches with sodium
intake was independent of BP, we addi-
tionally adjusted for the most recent BP. We
performed all statistical analyses using SAS
AJPH RESEARCH
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version 9.4 (SAS Institute, Cary, NC). We
considered a P value of less than .05 (2 sides)
statistically signiﬁcant.
RESULTS
Table 1 displays the baseline character-
istics of all TONE study participants by as-
signment to the NaD intervention or
control. Of the 975 individuals, 52% were
men, 76% were White, and the mean (SD)
age was 65.8 (4.6) years. Mean (SD) 24-hour
urinary sodium excretion at baseline was
148.5 (54) millimoles per 24 hours. Overall,
there was no statistically signiﬁcant differ-
ence in baseline characteristics by group
(NaD vs control).
Participant attendance rates were 90%,
86%, and 86% at the 9-, 18-, and 30-month
follow-up visits. BP measurements were
available for 100% of the visits. We collected
24-hour urine samples in 867 (88.9%),
804 (82.5%), and 421 (82.1%) participants at
the 9-, 18-, and 30-month visits,
respectively.
Urinary Sodium Excretion and
Headache Occurrence
Baseline urinary sodium excretion did
not differ between the NaD and control
groups (Table A, available as a supplement
to the online version of this article at
http://www.ajph.org). We observed signif-
icantly greater reductions in urinary sodium
from baseline in the NaD group compared
with the control group at the 9-, 18-, and
30-month follow-up visits. The mean
changes in urinary sodium excretion in the
NaD group were –40.9, –43.2, and –45.3
millimoles per 24 hours at the 9-, 18-, and
30-month follow-up visits, respectively.
Corresponding mean changes in the control
groupwere 0.4, –3.1, and –4.5millimoles per
24 hours, respectively. During follow-up, the
mean between-group difference in average
urinary sodium excretion was 38.8 milli-
moles per 24 hours.
During follow-up, 126 participants re-
ported headache as an adverse event, and 13
(10.3%) reported headache twice as an adverse
event. We used the ﬁrst reported headache as
our study outcome. Figure 1 displays the
cumulative incidence of headaches during
follow-up by randomized assignment. In the
control group, 14.3% reported headaches
during follow-up. By contrast, only 10.5%
reported headaches in the NaD group (log-
rank test, P= .012).
The HR for headaches in the NaD
group compared with control was 0.56
(95% CI = 0.38, 0.83; P= .01) after adjust-
ment for clinical center, time-varying drug
withdrawal status, and average weight loss
during follow-up (model 2). After further
adjustment for most recent systolic and di-
astolic BP before the occurrence of head-
aches (model 3), the HR was essentially
unchanged (HR= 0.59; 95% CI = 0.40,
0.88; P= .02). In the sensitivity analysis,
the HR for headaches (model 3) was
0.83 (95% CI = 0.49, 1.40; P= .48) in the
weight loos alone intervention, 0.61 (95%
CI = 0.39, 0.95; P= .03) in the NaD alone
intervention, and 0.47 (95%CI = 0.25, 0.92;
P= .03) in the combined weight loos and
NaD intervention compared with the con-
trol group.
Observational Analyses and
Dose–Response Relationship
Table 2 summarizes results from the
Cox proportion hazard models using average
urinary sodium excretion during follow-up as
the primary exposure. We identiﬁed a statis-
tically signiﬁcant direct association of head-
aches with average urinary sodium excretion.
After adjustment for clinical center, age,
smoking, race, gender, alcohol use, physical
activity, average weight loss during
follow-up, and drugwithdrawal status (model
2), a 10 millimoles per 24 hour higher level of
urinary sodium excretion was associated with
a hazard of headaches that was 7.0% higher
(95% CI= 4%, 11%, P £ .001). The associa-
tion between urinary sodium excretion and
risk of headaches persisted after further ad-
justment for most recent systolic BP and di-
astolic BP in model 3. Because headaches
were more common in women (17.0%) than
in men (8.8%), we further stratiﬁed our an-
alyses by gender. The magnitude of the as-
sociations was similar in both gender; the HR
of headaches associated with a 10 millimoles
per 24 hours higher level of urinary sodium
excretion was 1.09 (95% CI= 1.03, 1.15)
for men and 1.07 (95% CI= 1.02, 1.12) for
women.
In exploratory analyses, the relationship
between headaches and absolute urinary
sodium level appeared to be nonlinear, with
a threshold between 120 to 150 millimoles
per 24 hours. We noted the greatest evi-
dence for an association between urinary
sodium excretion and occurrence of head-
aches above this threshold. For this reason,
we categorized the participants into 3
groups on the basis of their average urinary
sodium excretion during follow-up: (1) less
TABLE 1—Baseline Characteristics of Participants by Randomly Assigned Group: Trial of
Nonpharmacologic Interventions in the Elderly, United States, 1992–1995
Characteristic
Control (n = 488),
Mean (SD) or %
Sodium Reduction (n = 487),
Mean (SD) or %
Alla (n = 975),
Mean (SD) or %
Age, y 65.8 (4.5) 65.8 (4.7) 65.8 (4.6)
Male 51.8 52.6 52.2
White 74.8 77.2 76.0
SBP, mmHg 128.1 (9.3) 128.4 (9.4) 128.2 (9.3)
DBP, mmHg 71.3 (7.4) 71.4 (7.2) 71.4 (7.3)
Urine sodium, mmol/24 h 148.6 (54.9) 148.4 (53.4) 148.5 (54.2)
Weight, lb 180.0 (26.3) 180.7 (28.4) 180.3 (27.4)
BMI, kg/m2 28.9 (3.5) 28.9 (3.6) 28.9 (3.5)
Alcohol user 34.8 35.5 35.2
Currently smokes 4.9 5.7 5.3
Note. BMI = body mass index; DBP =diastolic blood pressure; SBP = systolic blood pressure.
aWe used the Student t test and c2 test to compare continuous variables and discrete variables, re-
spectively. There were no statistically signiﬁcant differences (all P > .05) in baseline characteristics
between the control and sodium-reduction study groups.
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than 120 millimoles per 24 hours (below the
threshold, lower sodium intake), (2) 120–
150 millimoles per 24 hours (close to
threshold, moderate sodium intake), and (3)
more than 150 millimoles per 24 hours
(above threshold, higher sodium intake).
Compared with the category of lower so-
dium intake, individuals with moderate
sodium intake did not exhibit a signiﬁcantly
higher risk of headaches (HR= 1.26; 95%
CI = 0.74, 2.16; P= .39). However, in-
dividuals in the higher sodium intake cat-
egory had a signiﬁcantly higher risk of
headaches than did those in the lower
sodium intake category (HR= 2.32; 95%
CI = 1.48, 3.65; P £ .001).
During spline interpolation, we identiﬁed
knots at 120 millimoles per 24 hours and
150 millimoles per 24 hours. Above the
150 millimoles per 24 hours knot, an increase
of 10 millimoles per 24 hours in urinary so-
dium excretion was associated with an in-
crease of 9.7% in the hazard of headaches (95%
CI= 3.4%, 16.9%; P= .002) after adjusting for
age, smoking, race, gender, alcohol use,
physical activity, average weight loss during
follow-up, and drug withdrawal status. This
positive association remained signiﬁcant with
further adjustment for most recent BPs in
model 3 (HR=1.09; 95% CI=1.02, 1.18;
P= .004). The risk of headaches increased
dramatically and signiﬁcantly as the urinary
sodium excretion level was above the 150
millimoles per 24 hours (Figure A, available as
a supplement to the online version of this
article at http://www.ajph.org).
DISCUSSION
In this analysis of 975 persons, aged 60 to
80 years who participated in the TONE trial,
we found that NaD was associated with
a lower risk of headaches over the course of
36 months of follow-up. Speciﬁcally, in-
dividuals who were randomly assigned to
a NaD intervention had a lower cumulative
incidence of headaches than did their coun-
terparts in the control group. In an obser-
vational analysis, urinary sodium excretion,
measured as an average level during
follow-up, was associated with occurrence
of incident headaches, independent of other
risk factors, baseline headaches, use of BP
lowering medications, and most recent level
of BP. We observed an apparent threshold
effect, with the risk of headaches increasing
progressively above a urinary sodium excre-
tion of 150 millimoles per 24 hours. Above
the sodium excretion threshold of 150 mil-
limoles per 24 hours, risk of incident head-
aches was higher by 7.8% for every 10
millimoles average increase in 24-hour uri-
nary sodium; below this threshold, there
was no signiﬁcant relationship.
Although numerous studies have assessed
the effects of a reduced sodium intake on
BP6,7,11–13 and several studies have assessed
the relationship between headaches and
BP,4,5,16,17 the relationship between sodium
intake and the occurrence of headaches has
received scant attention. The most relevant
study is the DASH-Sodium trial, a random-
ized, controlled feeding study that tested the
effects of 3 levels of sodium intake (50,
100, and 150 mmol/24 hr) in 2 different diets
(the DASH diet and a typical American diet).
In a recent secondary analysis of this trial,
a reduced sodium intake was associated
with signiﬁcantly lower risk of headache
(odds ratio[OR]= 0.69; P= .05, among
those consuming a typical American diet,
and OR=0.69; P= .04, among those
TABLE 2—HR (95%CI) of Headaches by Level of Urinary Sodium Excretion During Follow-Up:
Trial of Nonpharmacologic Interventions in the Elderly, United States, 1992–1995
Model
Average Urinary Sodium
Excretion as a Continuous
Variable,a HR (95% CI)
Average Urinary Sodium
as Categorical Variableb
120–150 mmol/24 h,
HR (95% CI)
> 150 mmol/24 h,
HR (95% CI)
Model 1c 1.04 (1.00, 1.07) 1.01 (0.62, 1.66) 1.65 (1.11, 2.46)
Model 2d 1.07 (1.04, 1.11) 1.15 (0.67, 1.95) 2.27 (1.45, 3.55)
Model 3e 1.07 (1.04, 1.11) 1.26 (0.74, 2.16) 2.32 (1.48, 3.65)
Note. CI = conﬁdence interval; HR =hazard ratio. Cox proportional hazard models showing HR of
headaches associated with average urinary sodium excretion.
aHigher by 10 mmol/24 h.
b<120 mmol/24 h is the reference group.
cCox proportional hazards models adjusted for clinical center.
dModel 1 plus smoking, race, gender, age, alcohol use, baseline headache, average weight loss during
follow-up, physical activity and time-varying drug withdrawal status.
eModel 2 plusmost recent systolic blood pressure and diastolic blood pressure before the occurrence of
headaches.
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FIGURE 1—Cumulative Incidence of Headaches by Intervention Group (Reduced Sodium vs
Control): Trial of Nonpharmacologic Interventions in the Elderly, United States, 1992–1995
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consuming the DASH diet) in adults with
prehypertension and stage 1 hypertension.14
By contrast to TONE, study participants
in the DASH-Sodium trial tended to be
younger, with a mean (SD) age of 48 years.10
Also, the 2 trial designs and duration of
follow-up were different (a cross-over trial
with approximately 30 days of follow-up for
each period of intervention in the DASH-
Sodium trial and a parallel arm trial with
a median follow-up of 29 months in the
TONE trial), the extent of NaD was almost
twofold greater in the DASH-Sodium trial
than in theTONE trial, and themethods used
to ascertain headaches were different in
the 2 studies (symptom check list in the
DASH-Sodium trial and adverse event
reporting in the TONE trial). Overall, the
ﬁndings from our analysis and the corre-
sponding DASH-Sodium report provide
consistent evidence regarding the apparent
effect of sodium intake on the occurrence of
headaches. Because of the use of adverse
events reporting as the method of ascertain-
ment for headaches in the TONE trial, it
seems likely that the results from this trial
may have highlighted the relationship be-
tween NaD and more severe headaches.
Themechanisms underlying an association
between sodium intake and headaches are
uncertain. Sodium intake may be related to
headaches through a direct effect on BP or
indirectly through other BP-independent
mechanisms. Excessive intake of sodium is
a well-established risk factor for high BP, and
NaD can lower BP in hypertensive and
nonhypertensive individuals.6–13 Elevated BP
has been associated with headaches in-
dependent of weight status and antihyper-
tensive drug therapy.4,5 Therefore, it is
possible that a high intake of sodiummay lead
to headaches through a direct effect on BP.
However, controlling for recent BP in the
Cox regression models did not attenuate the
association between sodium and headaches in
our analyses, suggesting that the effect of
sodium on headaches might be independent
of BP.
One proposed BP-independent mecha-
nism relates to changes in vascular smooth
muscle tone. Sodium intake is an important
determinant of smooth muscle cell reactivity,
which is in part mediated by changes in ex-
tracellular volume and perhaps by changes
in intracellular calcium. A high sodium
intake increases the reactivity of arterioles
and the BP response to stress or sympathetic
simulation.18 In a study of patients with
asthma, a moderate reduction in sodium
intake led to an improvement in asthma
symptoms, potentially related to changes
in bronchial smooth muscle tone.19 Such
ﬁndings suggest that nonvascular headaches
might be part of a continuum with vascular
headaches at 1 extreme.20 Still, we cannot
totally rule out an effect of BP in our study
because we measured BP at prespeciﬁed
follow-up visits, not at the time of the
headaches.
Strengths and Limitations
Our study has several strengths. First, the
sample size of TONE trial was relatively large
(n = 975), and the duration of follow-up was
relatively long (up to 3 years). Second, we
collected information on potential adverse
events at each study visit; a study clinician
who was blinded to the participant’s treat-
ment allocation veriﬁed these. Third, we
estimated sodium intake bymeans of carefully
collected 24-hour urine samples, with aver-
aging of several samples for the observational
analyses: twice before randomization and
once at the 9-month, 18-month, and
30-month follow-up visits. Of the available
methods, mean 24-hour urinary excretion of
sodium collected from multiple occasions
provides the most accurate estimate of dietary
sodium intake for observational analyses.21
Study limitations include a lack of speciﬁc
information regarding participant headaches
severity and duration and prior history of
headaches.
Nevertheless, headaches reported as an ad-
verse event in TONE were associated with
baseline headache experience,22 and we ad-
justed for baseline headaches in our observa-
tional analyses. Again, because we did not
measured BP at the time of the event, in-
ferences about the relationship betweenBP and
headaches are uncertain. However, there were
no differences when we compared BP mea-
sured at the study visit closest to the adverse
event and the averageBPduring the follow-ups
for study participants. The average time be-
tween most recent BP measurement and oc-
currence of adverse event headache was 12.3
days for thosewhohad adverse event headache,
which is relative short.Although the assortment
of headaches in this study is probably not
subject to reporting bias or directly related to
the intervention assignments, we were unable
to rule out the possibility that the observed
improvement inoccurrenceof headaches in the
NaD group could be a surrogate of improving
general well-being.
Conclusions
Our ﬁndings suggest that reducing sodium
intake lowers the risk of headaches in older
persons with hypertension. Our ﬁndings are
consistent with results from the DASH-
Sodium trial, which enrolled a middle-aged
study population and used a different ap-
proach to ascertainment. Whether a reduced
sodium intake lowers the risk of headaches in
other populations (e.g., personswithmigraine
headaches) is unknown. From a policy per-
spective, these data provide an additional
rationale in support of recommendations by
the American Heart Association, US federal
government, Institute of Medicine, World
Health Organization, and others to reduce
dietary sodium intake.23
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